**WEB REQUIREMENTS**

|  |  |  |  |
| --- | --- | --- | --- |
| **Project Name (internal)** | 2015 Gyn Conference Webcast | **Project Code** | PB5LCN001 |
| **Virtual Project Manager** | Jae Eising | **Clinical Program Manager** | Amy Furedy |
| **Compliance** | Briana Devaser | **Editor** | Heather Tomlinson |

**Launch Date/Internal Launch Date:**

**1 March 2015**

**Project Type**

Webcast

Downloadable Slides

CD/DVD

Podcast

Other:

**Email Blast Included?**

Yes

No

**Number of E-Blasts**

Only One

Two

Three  
Other Amount:

Dates to Blast or Special Requests: Early March

**Cross Promotion**

Yes

No

If Yes, List Activities:

**Target Audience**

US  
EX-US  
Global (Both EX-US & US)  
Other or Special:

Additional Emails (Supporters?):

**Slides**

Slides Included

Yes

No

Slide Location:

Slides Available By: 5 Feb 2015

**Slides Synched? (if included in webcast)**

Yes

No

**Webpage Content (All Copy)**

Content Status (Final/Approved):

**CME?**

Yes

No

**CME Posttest Link:**

**Webcast URL:** [**www.prIMEoncology.org/webcast-gynconference2015**](http://www.prIMEoncology.org/webcast-gynconference2015)

**Additional Components**

Cases with Voting

Polls

Video Segmentation

Table of Contents

Other:

**Mobile App Title: Webcast 2015 Gynecologic Oncology Conference Barcelona**

**LIVE MEETING-ASSOCIATED VIRTUAL ACTIVITIES**

**WEB URL:** [**www.prIMEoncology.org/webcast-gynconference2015**](http://www.prIMEoncology.org/webcast-gynconference2015)

1. **[Insert Meeting Title]**

**ACTIVITY FEATURES**

[Icon] Interactive Presentation

[Icon] Downloadable Slides

[Icon] Podcast (if appropriate)

[Icon] CME-Certified (if appropriate)

[Insert screen shot]

1. **ACTIVITY OVERVIEW**

**WEBCAST**

This CME-certified Webcast contains **video and downloadable slides** from the meeting 2015 Progress and Controversies in Gynecologic Oncology Conference, a prIME Oncology educational activity that was held on 16-17 January 2015, in Barcelona, Spain.

1. **PROVIDER**

This activity is provided by prIME Oncology.

1. **SUPPORTER**

This educational activity is supported by AstraZeneca and F. Hoffmann-La Roche Ltd.

1. **TOPICS – *for Webcast***

**Session I Cervical Cancer and Vulvar Cancer**

Current status of treatment for vulvar cancer

*Sven Mahner, MD, PhD*

Technical innovations in robotic surgery

*Jan Persson, MD, PhD*

Update on neoadjuvant chemotherapy in cervical cancer

*Nicoletta Colombo, MD*

Update on targeted therapy and immunotherapy for cervical cancer

*Bradley J. Monk, MD, FACS, FACOG*

**Session II Endometrial Cancer and Beyond**

Debate

Role of radiotherapy in grade 3 FIGO IB endometrial cancer

*Pro Radiotherapy: Alexandra Taylor, MBBS, MD*

*Contra Radiotherapy: Mansoor Mirza, MD*

Treatment of recurrent endometrial cancer and evaluation of new agents

*Andrés Poveda, MD*

What are the oncologic risks of morcellation of the uterus?

Frédéric Amant, MD, PhD

**Session III Ovarian Neoplasm I: Emerging Concepts**

The impact of molecular testing on therapeutic decisions in ovarian cancer

*Michael Birrer, MD, PhD*

Evolving role of upfront and postoperative imaging in ovarian cancer

*Vincent Vandecaveye, MD, PhD*

Future of targeted agents and combinations in ovarian cancer

*Stanley B. Kaye, MD*

**Session IV Ovarian Neoplasm II: Practical Applications in the First-Line Setting**

Personalized medicine: Identification and treatment of fragile patients

*Felix Hilpert, MD, DMSci*

Debate: HIPEC plays a role in treatment of advanced ovarian cancer

*Pro: Anna Fagotti, MD, PhD*

*Contra: Philipp Harter, MD*

**Session V Borderline Ovarian Tumors**

Pathologist’s view on the current status of borderline tumors

*Jaime Prat, MD, FRCPath*

Clinical aspects: Fertility-sparing surgery of borderline ovarian tumors

*Philippe Morice, MD*

**Session VI Ovarian Neoplasm III: Recurrence**

Interactive Clinical Case:

Platinum-resistant disease

*Ignace Vergote, MD, PhD*

Interactive Clinical Case:

Platinum-sensitive disease

*Andreas du Bois, MD, PhD*

Ovarian cancer patients who have received multiple prior therapies: When to stop or continue treatment?

*Eric Pujade-Lauraine, MD, PhD*

**7. FACULTY**

**Meeting Chairs**

|  |  |
| --- | --- |
| **Andreas du Bois, MD, PhD**  Kliniken Essen-Mitte  Essen, Germany  **Stanley B. Kaye, MD**  The Royal Marsden Hospital  Sutton, United Kingdom  **Scientific Committee**  **Nicoletta Colombo, MD**  University of Milan-Bicocca  Milan, Italy  **Bradley J. Monk, MD, FACS, FACOG**  Creighton University School of Medicine  St Joseph's Hospital and Medical Center  Phoenix, Arizona, United States | **Ignace Vergote, MD, PhD**  University Hospital Gasthuisberg  Leuven, Belgium  **Andrés Poveda, MD**  Fundacion Instituto Valenciano de Oncología  Valencia, Spain    **Eric Pujade-Lauraine, MD, PhD**  Centre Hospitalier Universitaire Hôtel-Dieu  Paris, France |

**Faculty**

|  |  |
| --- | --- |
| **Frédéric Amant, MD, PhD**  Catholic University  Leuven, Belgium  **Michael Birrer, MD, PhD**  Massachusetts General Hospital  Boston, Massachusetts, United States  **Anna Fagotti, MD, PhD**  Catholic University of the Sacred Heart  Rome, Italy  **Philipp Harter, MD**  Kliniken Essen-Mitte  Essen, Germany  **Felix Hilpert, MD, DMSci**  Christian-Albrechts-University of Kiel  Kiel, Germany  **Sven Mahner, MD, PhD**  University Medical Center Hamburg-Eppendorf  Hamburg, Germany | **Mansoor Mirza, MD**  Rigshospitalet  Copenhagen, Denmark  **Philippe Morice, MD**  Institute Gustave Roussy  Villejuif, France  **Jan Persson, MD, PhD**  Lund University  Lund, Sweden  **Jaime Prat, MD, FRCPath**  Hospital de la Santa Creu i Sant Pau  Barcelona, Spain  **Alexandra Taylor, MBBS, MD**  The Royal Marsden Hospital  London, United Kingdom  **Vincent Vandecaveye, MD, PhD**  University of Leuven  Leuven, Belgium |

**8. TARGET AUDIENCE**

The 2015 Progress and Controversies in Gynecologic Oncology Conference is intended for gynecologists, oncologists, radiation therapists, surgeons, pathologists, and other practitioners including allied health professionals involved in the diagnosis and management of gynecologic malignancies.

**9. LEARNING OBJECTIVES**

After successful completion of this educational activity, participants should be able to:

* Develop a practical approach to cervical cancer and vulvar cancer disease management
* Discuss the role of radiotherapy and systemic therapies in the management of endometrial cancer
* Derive the optimal management of ovarian cancer in the first-line setting based on disease stage and clinical presentation
* Assess standard and emerging therapeutic options for recurrent ovarian cancer and discuss their impact on patient outcomes

**10. CONTINUING MEDICAL EDUCATION [if applicable]**

**Replace the EACCME language w/ the ACCME language from our ACD template as the webcast is ACCME**

**11. METHOD OF PARTICIPATION [if applicable]**

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology's database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the [Terms of Use.](http://www.primeoncology.org/footer-e-pages/terms_of_use.aspx)

Links to the posttest are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with XX% or higher.

**12. DISCLOSURES [if applicable]**

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr du Bois has disclosed that he has received grants and research support from Roche and AstraZeneca (institution; not personally). He has also received honoraria or consultation fees from Roche, AstraZeneca, Pharmamar, and MSD. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Kaye has disclosed that he has received honoraria or consultation fees from AstraZeneca and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Vergote has disclosed that he has served as a consultant and/or advisory board member for Amgen NV, Array Biopharma, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Eli Lilly, Endocyte, Fresenius, GE Healthcare, GlaxoSmithKline, Intuitive Surgical, Janssen-Cilag, Menarini Ricerche SPA, Merck Sharp & Dohme, Morphotek, Nektar Therapeutics, Novo Nordisk Pharma, Oasmia Pharmaceutical AB, Pharmamar, Phillips Gilmore Oncology, Quintiles Belgium, F. Hoffmann-La Roche Ltd, Sanofi-Aventis, Shering-Plough, Sigma-Tau Pharmaceuticals, Telik, and TRM Oncology BV. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Colombo has disclosed that she has received honoraria or consultation fees from Roche, Pharmamar, Amgen, Merck, GlaxoSmithKline, and MSD. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Monk has disclosed that he has received grants and research support from Novartis, Amgen, Genentech, Lilly, Janssen/Johnson&Johnson, Array, and TESARO. He has also received honoraria or consultation fees from GlaxoSmithKline, Merck, TESARO, Boehringer Ingelheim, Roche/Genentech, and AstraZeneca. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Poveda has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Pujade-Lauraine has disclosed that he has received honoraria or consulting fees from Roche, AstraZeneca, GSK, Boehringer-Ingelheim, Merck, and Pharmamar. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Amant has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Birrer has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Fagotti has no relevant financial relationships to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Harter has disclosed that he has received honoraria or consulting fees from AstraZeneca, Roche, Takeda, and MSD. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Hilpert has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Mahner has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Mirza has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Morice has disclosed that he has received honoraria or consulting fees from Roche and AstraZeneca. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Persson has disclosed that he has received honoraria or consulting fees from Intuitive Surgical. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Prat has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Taylor has no relevant financial relationships to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Vandecaveye has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

* Bojana Pajk, MD, MSc (clinical content reviewer/planner) – no relevant financial relationships
* Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

**13. ACTIVITY DATE**

Release Date 1 March 2015

Expiration Date 29 February 2016

**14. MOBILE APP VIEW ACTIVITY TEXT PER VIDEO**Insert presentation-specific text for the “View Activity” action item on the mobile app. *[copy from live meeting - the symposia webcast mobile app titles are exactly the same as the symposia app title (since once the live meeting has occurred, that title is no longer in use and it is easier for users to associate the enduring activity with the live activity that way.]*

1. **Web Activity Page Titles**

Landing Page Title: *[www.prIMEoncology.org/webcast-gynconference2015](http://www.prIMEoncology.org/webcast-gynconference2015)*   
Activity Page Title: *[Presentation Titles]🡪 see* ***5. Topics***

1. **Meta Description  
   (One description for each page (including landing pages and all activity pages.** Webcast and downloadable slides from prIME Oncology’s *2015 Progress and Controversies in Gynecologic Oncology Conference*, held in Barcelona.
2. **Key Words and Key Phrases  
   (Please included as many key words or phrases as are associated with the activity. 15 or more is ideal. These are words or phrases that a viewer might use in a web search. Please add one key word/phrase per line) Example:***cervical cancer*

vulvar cancer

neoadjuvant chemotherapy

targeted therapy

immunotherapy

bevacizumab

endometrial cancer

radiotherapy

recurrent endometrial cancer

morcellation

uterus

ovarian cancer

ovarian neoplasm

molecular testing

imaging

PARP inhibitors

MEK inhibitors

VEGF inhibitors

olaparib

BRCA

cediranib

fragile patients

first-line setting

HIPEC

borderline ovarian tumors

fertility-sparing surgery

platinum-resistant ovarian cancer

platinum-sensitive ovarian cancer

later-line treatment for ovarian cancer

trebananib

carboplatin

paclitaxel

cisplatin

pegylated liposomal doxorubicin

gemcitabine

nintedanib

fosbretabulin

niraparib

rucaparib

pazopanib

1. **E-blast Subject Header**

New Webcast: 2015 Progress and Controversies in Gynecologic Oncology Conference